Demant A/S (WILYY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Demant A/S (WILYY) trades at $22.09 with AI Score 52/100 (Grade B). Demant A/S is a global hearing healthcare and audio technology company. Market cap: $9.32B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for WILYY: WILYY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WILYY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
WILYY: 2/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Demant A/S (WILYY) Healthcare & Pipeline Overview
Demant A/S, founded in 1904, is a global leader in hearing healthcare and audio technology. The company operates through its Hearing Healthcare and Communications segments, providing hearing solutions and communication headsets. With a market capitalization of $9.32B, Demant serves customers internationally, focusing on enhancing hearing and communication.
What Is the Investment Thesis for WILYY?
Demant A/S presents a compelling investment case based on its established position in the growing hearing healthcare and audio technology markets. The company's diverse product portfolio, spanning hearing implants/aids and communication headsets, allows it to capture opportunities across multiple segments. With a market capitalization of $9.32B and a profit margin of 6.7%, Demant demonstrates financial stability. Growth catalysts include expanding its global footprint, particularly in emerging markets, and introducing innovative hearing solutions. Potential risks include increased competition, regulatory changes, and fluctuations in currency exchange rates. The company's P/E ratio of 25.65 reflects investor expectations of future growth.
Based on FMP financials and quantitative analysis
WILYY Key Highlights
- Market capitalization of $9.32B, reflecting a significant presence in the hearing healthcare and audio technology market.
- Profit margin of 6.7%, indicating efficient operations and profitability.
- Gross margin of 69.9%, showcasing strong pricing power and cost management.
- Beta of 0.82, suggesting lower volatility compared to the overall market.
- Employs 19,917 individuals globally, highlighting its operational scale.
Who Are WILYY's Competitors?
WILYY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDUUF Bangkok Dusit Medical Services Public Company Limited | $0.60 | -6.25% | $9.54B | 52 |
| ESAIY Eisai Co., Ltd. | $6.66 | +2.78% | $7.52B | 55 |
| ESALF Eisai Co., Ltd. | $25.00 | +0.00% | $7.05B | 61 |
| GIFOF Grifols, S.A. | $8.85 | +0.00% | $8.70B | 52 |
| GNGBY Getinge AB (publ) | $21.24 | +0.80% | $5.78B | 47 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WILYY's Key Strengths?
- Strong global presence and distribution network.
- Diverse product portfolio across hearing healthcare and communication.
- Established brand reputation and customer loyalty.
- Commitment to innovation and product development.
What Are WILYY's Weaknesses?
- Exposure to currency exchange rate fluctuations.
- Dependence on regulatory approvals for new products.
- Intense competition in the hearing healthcare market.
- Potential for product recalls or liability claims.
What Could Drive WILYY Stock Higher?
- Launch of new hearing aid products with advanced features in Q4 2026.
- Expansion of the EPOS brand in the gaming headset market.
- Increasing demand for hearing healthcare solutions due to an aging population.
What Are the Key Risks for WILYY?
- Increased competition from established and emerging players in the hearing healthcare market.
- Fluctuations in currency exchange rates that could impact financial results.
- Regulatory changes in the healthcare industry that could affect product approvals and reimbursement policies.
What Are the Growth Opportunities for WILYY?
- Expansion in Emerging Markets: Demant has the opportunity to expand its presence in emerging markets, such as China and India, where the demand for hearing healthcare solutions is growing rapidly. These regions have a large aging population and increasing awareness of hearing loss, creating a significant market opportunity. By establishing strategic partnerships and tailoring its products to local needs, Demant can capture a larger share of these markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- Innovation in Hearing Aid Technology: Demant can continue to invest in research and development to create more advanced and personalized hearing aid solutions. This includes developing hearing aids with improved sound quality, noise reduction capabilities, and connectivity features. By staying at the forefront of technological innovation, Demant can differentiate itself from competitors and attract a larger customer base. The market for advanced hearing aids is expected to grow as consumers demand more sophisticated and effective solutions.
- Growth in the EPOS Brand: Demant can further develop and expand its EPOS brand of communication headsets for collaborative work and gaming markets. The rise of remote work and e-sports has created a growing demand for high-quality headsets with superior audio performance and comfort. By focusing on product innovation and marketing, Demant can increase the market share of the EPOS brand and drive revenue growth. The global headset market is projected to continue its expansion in the coming years.
- Strategic Acquisitions: Demant can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This includes acquiring companies with complementary technologies or market access in key regions. By carefully selecting and integrating acquisitions, Demant can accelerate its growth and strengthen its competitive position. The company has a track record of successful acquisitions and can leverage its expertise to create value through future deals.
- Development of Telehealth Solutions: Demant can develop and offer telehealth solutions for hearing care, allowing patients to receive remote consultations, hearing tests, and adjustments to their hearing aids. This can improve access to care, particularly for patients in rural areas or those who have difficulty traveling to clinics. Telehealth solutions can also reduce costs and improve efficiency for healthcare providers. The market for telehealth services is growing rapidly, driven by technological advancements and changing consumer preferences.
What Opportunities Does WILYY Have?
- Expansion into emerging markets with growing demand for hearing healthcare.
- Development of telehealth solutions for remote hearing care.
- Growth in the communication headset market due to remote work and e-sports.
- Strategic acquisitions to expand product portfolio and geographic reach.
What Threats Does WILYY Face?
- Increased competition from established and emerging players.
- Changes in government regulations and reimbursement policies.
- Economic downturns that could reduce consumer spending on healthcare.
- Technological disruptions that could render existing products obsolete.
What Are WILYY's Competitive Advantages?
- Strong brand reputation in the hearing healthcare market.
- Extensive distribution network and global reach.
- Technological innovation and product development capabilities.
- Vertical integration across the hearing healthcare value chain.
What Does WILYY Do?
Demant A/S, headquartered in Smørum, Denmark, has a rich history dating back to 1904. Originally known as William Demant Holding A/S, the company changed its name to Demant A/S in March 2019. Demant operates in the healthcare sector, specifically within the medical devices industry. The company functions through two primary segments: Hearing Healthcare and Communications. The Hearing Healthcare segment develops, manufactures, and sells hearing implants and aids, hearing care solutions, and diagnostic products. This segment addresses various hearing needs, from mild to profound hearing loss. The Communications segment provides high-end headsets for collaborative work and gaming markets under the EPOS brand. These headsets focus on delivering superior audio quality and comfort for professional and recreational use. Demant has a global presence, serving customers in Europe, North America, the Pacific, Asia, and other international markets. The company employs 19,917 individuals and is committed to enhancing people's hearing and communication capabilities through innovative technology and solutions.
What Products and Services Does WILYY Offer?
- Develops and manufactures hearing implants and aids.
- Provides hearing care solutions through its network of clinics.
- Offers diagnostic products for audiological testing.
- Manufactures and sells communication headsets under the EPOS brand.
- Provides solutions for collaborative work environments.
- Offers headsets for the gaming market.
- Distributes products in Europe, North America, Asia, and internationally.
How Does WILYY Make Money?
- Sells hearing healthcare products and services directly to consumers and through distributors.
- Generates revenue from the sale of communication headsets to businesses and consumers.
- Provides hearing care services through its network of clinics.
- Partners with healthcare professionals and audiologists to promote its products.
What Industry Does WILYY Operate In?
Demant A/S operates within the medical devices industry, specifically focusing on hearing healthcare and audio technology. The global hearing aid market is projected to grow, driven by an aging population and increasing awareness of hearing loss. The communication headset market is also expanding, fueled by the rise of remote work and e-sports. Demant competes with companies like BDUUF (Sonova Holding AG), ESAIY (Amplifon SpA), ESALF (William Grant & Sons Ltd), GIFOF (Sivantos Pte. Ltd.), and GNGBY (GN Store Nord A/S). Demant's focus on innovation and global expansion positions it to capitalize on these market trends.
Who Are WILYY's Key Customers?
- Individuals with hearing loss.
- Businesses and organizations requiring communication headsets.
- Audiologists and hearing care professionals.
- Gamers and e-sports enthusiasts.
Company Profile
Demant A/S operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Smørum, DK. The company is led by CEO Søren Nielsen. WILYY has traded publicly since 2011.
How Demant A/S Is Valued
Demant A/S carries a market capitalization of $9.32B, placing it in the mid-cap category. Relative to its peer group, WILYY's quantitative score of 52/100 is roughly in line with the peer average of 53/100.
ROE 16%Key Financial Metrics
Return on equity for Demant A/S stands at 16.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.0%, showing how much profit it generates from its asset base. WILYY trades at a trailing price-to-earnings ratio of 38.04, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Demant A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.49 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Demant A/S revenue of about $25.12B for fiscal 2026, with EPS near $6.34. The estimate reflects 10 contributing analysts.
WILYY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong global presence and distribution network.
- Diverse product portfolio across hearing healthcare and communication.
- Established brand reputation and customer loyalty.
- Commitment to innovation and product development.
Bear Case
- Exposure to currency exchange rate fluctuations.
- Dependence on regulatory approvals for new products.
- Intense competition in the hearing healthcare market.
- Potential for product recalls or liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
WILYY Latest News
No recent news available for WILYY.
WILYY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WILYY.
Price Targets
Wall Street price target analysis for WILYY.
WILYY MoonshotScore
What does this score mean?
The MoonshotScore rates WILYY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Søren Nielsen
CEO
Søren Nielsen serves as the CEO of Demant A/S, leading a global organization with nearly 20,000 employees. His career spans various leadership roles within the healthcare and technology sectors. Nielsen brings extensive experience in strategic management, product development, and international expansion. He is known for his focus on innovation and customer-centric solutions. His leadership is focused on driving growth and maintaining Demant's position as a leader in hearing healthcare and audio technology.
Track Record: Under Søren Nielsen's leadership, Demant A/S has continued to expand its global presence and invest in innovative hearing solutions. He has overseen the launch of new products and the expansion of the EPOS brand in the communication headset market. Nielsen has also focused on improving operational efficiency and driving sustainable growth. His strategic decisions have contributed to Demant's financial performance and market leadership.
Demant A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. WILYY is an ADR representing shares of Demant A/S, allowing U.S. investors to invest in the company without directly dealing with the Danish stock market. This simplifies trading and reduces complexities associated with international investing.
- Home Market Ticker: Copenhagen Stock Exchange (Nasdaq Copenhagen), Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: WILY
WILYY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and regulatory oversight compared to exchange-listed companies. This tier is also known as the Grey Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Potential for price manipulation.
- Higher risk of fraud or misrepresentation.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and compliance history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established history as Demant A/S since 1904.
- Global presence in the hearing healthcare market.
- Operations in two segments: Hearing Healthcare and Communications.
- ADR status, indicating some level of regulatory oversight.
WILYY Healthcare Stock FAQ
What does Demant A/S do?
Demant A/S is a global hearing healthcare and audio technology company that develops, manufactures, and sells products and equipment to enhance people's hearing. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand. Demant serves customers in Europe, North America, Asia, and internationally.
What do analysts say about WILYY stock?
Analyst consensus on WILYY stock is currently mixed, reflecting the company's position in a competitive market. Key valuation metrics, such as the P/E ratio of 25.65, suggest that investors expect future growth. Growth considerations include the company's expansion in emerging markets and its investment in innovative hearing solutions. Analysts also note the potential impact of currency exchange rate fluctuations and regulatory changes on the company's financial performance.
What are the main risks for WILYY?
The main risks for WILYY include increased competition in the hearing healthcare market, fluctuations in currency exchange rates, and regulatory changes in the healthcare industry. The company also faces the risk of product recalls or liability claims. Additionally, economic downturns could reduce consumer spending on healthcare, impacting the company's financial results. These risks could affect Demant's profitability and market position.
What are the key factors to evaluate for WILYY?
Demant A/S (WILYY) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does WILYY data refresh on this page?
WILYY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven WILYY's recent stock price performance?
Demant A/S (WILYY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong global presence and distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WILYY overvalued or undervalued right now?
Valuing Demant A/S (WILYY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying WILYY?
Before investing in Demant A/S (WILYY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Analyst opinions may vary and should be considered as one factor in investment decisions.
- OTC market data may be less reliable than exchange-listed data.